WO1998045704A3 - A method for extracting quantitative information relating to an influence on a cellular response - Google Patents

A method for extracting quantitative information relating to an influence on a cellular response Download PDF

Info

Publication number
WO1998045704A3
WO1998045704A3 PCT/DK1998/000145 DK9800145W WO9845704A3 WO 1998045704 A3 WO1998045704 A3 WO 1998045704A3 DK 9800145 W DK9800145 W DK 9800145W WO 9845704 A3 WO9845704 A3 WO 9845704A3
Authority
WO
WIPO (PCT)
Prior art keywords
component
influence
protein
protein kinase
luminophore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1998/000145
Other languages
French (fr)
Other versions
WO1998045704A2 (en
Inventor
Ole Thastrup
Bjoern Sara Petersen
Soeren Tullin
Almholt Kasper
Kurt Scudder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998045704(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK01204477T priority Critical patent/DK1199564T3/en
Priority to AT98913541T priority patent/ATE215227T1/en
Priority to JP54227698A priority patent/JP2001522454A/en
Priority to DK03028919T priority patent/DK1435519T3/en
Priority to CA002286293A priority patent/CA2286293C/en
Priority to DE69804446T priority patent/DE69804446T3/en
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to EP98913541A priority patent/EP0986753B2/en
Priority to DK98913541T priority patent/DK0986753T4/en
Priority to AU68209/98A priority patent/AU6820998A/en
Publication of WO1998045704A2 publication Critical patent/WO1998045704A2/en
Publication of WO1998045704A3 publication Critical patent/WO1998045704A3/en
Priority to US09/417,197 priority patent/US6518021B1/en
Anticipated expiration legal-status Critical
Priority to US10/072,036 priority patent/US8058008B2/en
Priority to US11/927,246 priority patent/US20090023598A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Cells are genetically modified to expresss a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence. Measurement of redistribution is performed by recording of light intensity, fluorescence lifetime, polarization, wavelength shift, resonance energy transfer, or other properties by an apparatus consisting of e.g. a fluorescence microscope and a CCD camera. Data stored as digital images are processed to numbers representing the degree of redistribution. The method can be used as a screening program for identifying a compound that modulates a component and is capable of treating a disease related to the function of the component.
PCT/DK1998/000145 1997-04-07 1998-04-07 A method for extracting quantitative information relating to an influence on a cellular response Ceased WO1998045704A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK98913541T DK0986753T4 (en) 1997-04-07 1998-04-07 Method for extracting quantitative information as to the influence of a cellular response
EP98913541A EP0986753B2 (en) 1997-04-07 1998-04-07 A method for extracting quantitative information relating to an influence on a cellular response
AT98913541T ATE215227T1 (en) 1997-04-07 1998-04-07 METHOD FOR OBTAINING QUANTITATIVE INFORMATION ABOUT INFLUENCES ON CELLULAR REACTIONS
JP54227698A JP2001522454A (en) 1997-04-07 1998-04-07 How to extract quantitative information on the effects on cellular responses
DK03028919T DK1435519T3 (en) 1997-04-07 1998-04-07 Method of screening substances for effect on cAMP levels based on intracellular translocation of PKA
CA002286293A CA2286293C (en) 1997-04-07 1998-04-07 A method for extracting quantitative information relating to an influence on a cellular response
DE69804446T DE69804446T3 (en) 1997-04-07 1998-04-07 METHOD FOR REMOVING QUANTITATIVE INFORMATION ON INFLUENCES OF CELLULENT REACTIONS
DK01204477T DK1199564T3 (en) 1998-04-07 1998-04-07 Method of screening substances for effect on intracellular translocation
AU68209/98A AU6820998A (en) 1997-04-07 1998-04-07 A method for extracting quantitative information relating to an influence on a cellular response
US09/417,197 US6518021B1 (en) 1997-04-07 1999-10-07 Method for extracting quantitative information relating to an influence on a cellular response
US10/072,036 US8058008B2 (en) 1997-04-07 2002-02-05 Method for extracting quantitative information relating to an influence on a cellular response
US11/927,246 US20090023598A1 (en) 1997-04-07 2007-10-29 Method for extracting quantitative information relating to an influence on a cellular response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0392/97 1997-04-07
DK39297 1997-04-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/417,197 Continuation US6518021B1 (en) 1997-04-07 1999-10-07 Method for extracting quantitative information relating to an influence on a cellular response

Publications (2)

Publication Number Publication Date
WO1998045704A2 WO1998045704A2 (en) 1998-10-15
WO1998045704A3 true WO1998045704A3 (en) 1999-04-22

Family

ID=8092994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1998/000145 Ceased WO1998045704A2 (en) 1997-04-07 1998-04-07 A method for extracting quantitative information relating to an influence on a cellular response

Country Status (11)

Country Link
US (3) US6518021B1 (en)
EP (3) EP1435519B1 (en)
JP (1) JP2001522454A (en)
AT (3) ATE354089T1 (en)
AU (1) AU6820998A (en)
CA (1) CA2286293C (en)
DE (4) DE69837118T2 (en)
DK (2) DK1435519T3 (en)
ES (2) ES2191575T3 (en)
PT (2) PT986753E (en)
WO (1) WO1998045704A2 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226203B1 (en) 1996-01-26 2008-06-30 Virco B V B A Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
US7062219B2 (en) 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
US6416959B1 (en) 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6759206B1 (en) 1997-02-27 2004-07-06 Cellomics, Inc. System for cell-based screening
US7853411B2 (en) 1997-02-27 2010-12-14 Cellomics, Inc. System for cell-based screening
WO1998045704A2 (en) * 1997-04-07 1998-10-15 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
US7160687B1 (en) 1997-05-29 2007-01-09 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US20050221280A1 (en) 1998-02-02 2005-10-06 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling
US6388788B1 (en) 1998-03-16 2002-05-14 Praelux, Inc. Method and apparatus for screening chemical compounds
US20030036855A1 (en) 1998-03-16 2003-02-20 Praelux Incorporated, A Corporation Of New Jersey Method and apparatus for screening chemical compounds
AU765703B2 (en) * 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6037133A (en) * 1998-04-17 2000-03-14 Clontech Laboratories, Inc. IκBEGFP constructs, cell lines and methods of use
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
AU6189999A (en) * 1998-10-15 2000-05-08 Bioimage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targetting
EP1121593A2 (en) * 1998-10-15 2001-08-08 BioImage A/S Method for extracting quantitative information relating to an influence on a cellular response
GB9901072D0 (en) * 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
JP3576491B2 (en) * 1999-02-26 2004-10-13 セロミックス インコーポレイテッド System for cell-based screening
DE19915310A1 (en) * 1999-04-03 2000-10-05 Bayer Ag Diffusion-controlling sensor layer
EP1048952B1 (en) * 1999-04-29 2003-03-26 Erasmus Universiteit Rotterdam Determining analyte mobility
WO2000070528A2 (en) * 1999-05-14 2000-11-23 Cytokinetics, Inc. Method and apparatus for predictive cellular bioinformatics
US6651008B1 (en) 1999-05-14 2003-11-18 Cytokinetics, Inc. Database system including computer code for predictive cellular bioinformatics
US6743576B1 (en) 1999-05-14 2004-06-01 Cytokinetics, Inc. Database system for predictive cellular bioinformatics
US7151847B2 (en) 2001-02-20 2006-12-19 Cytokinetics, Inc. Image analysis of the golgi complex
US20030228565A1 (en) * 2000-04-26 2003-12-11 Cytokinetics, Inc. Method and apparatus for predictive cellular bioinformatics
EP1055929A1 (en) * 1999-05-26 2000-11-29 Tibotec N.V. Means and methods for drug discovery and the phenotypic characterisation of cells
US6573059B1 (en) * 1999-06-04 2003-06-03 Rmf Dictagene S.A. Use of the regulatory subunit of the camp dependent protein kinase (PKA) from dictyostelium for camp measurements
EP1101113A4 (en) * 1999-06-09 2002-05-08 Ljl Biosystems Inc Cell-signaling assays
US6673554B1 (en) 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
AU7131900A (en) * 1999-06-21 2001-01-09 Cellomics, Inc. A system for cell-based screening
US6121047A (en) * 1999-07-21 2000-09-19 Isis Pharmaceuticals Inc. Antisense modulation of SHP-1 expression
US6489151B1 (en) * 2000-03-27 2002-12-03 The Research Foundation Of State University Of New York Biologically active alternative form of the IKKα IκB kinase
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
KR100414641B1 (en) * 2000-04-07 2004-01-13 동부한농화학 주식회사 In vivo monitoring method of transgenic plants and system using the same
EP1276897A2 (en) * 2000-04-17 2003-01-22 BioImage A/S Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes
US20030162165A1 (en) * 2000-04-26 2003-08-28 Arkhammer Per O.G. Chemical signal enhancement of dynamic intensity-based intracellular protein-and fluorophore-based redistribution assays for drug-screening
US20020049544A1 (en) * 2000-06-23 2002-04-25 Cytokinetics, Inc. Image analysis for phenotyping sets of mutant cells
JP2004502434A (en) 2000-07-04 2004-01-29 バイオイメージ　エイ／エス A method for extracting quantitative information on interactions between cellular components
US7625951B2 (en) 2000-07-13 2009-12-01 University Of Kentucky Research Foundation Stimuli-responsive hydrogel microdomes integrated with genetically engineered proteins for high-throughput screening of pharmaceuticals
DE10037759A1 (en) * 2000-08-03 2002-07-04 Gruenenthal Gmbh screening process
KR100414781B1 (en) * 2000-11-24 2004-01-13 재단법인서울대학교산학협력재단 A cell-based stable assay system for monitoring NF-κB activity and a use thereof
US7218764B2 (en) 2000-12-04 2007-05-15 Cytokinetics, Inc. Ploidy classification method
US6956961B2 (en) 2001-02-20 2005-10-18 Cytokinetics, Inc. Extracting shape information contained in cell images
US7016787B2 (en) 2001-02-20 2006-03-21 Cytokinetics, Inc. Characterizing biological stimuli by response curves
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
EP1499885B1 (en) 2001-08-01 2009-10-21 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
AU2002358657A1 (en) * 2001-12-10 2003-06-23 Evotec Oai Ag Method for determining the influence of non-physiological compounds the derivatives and decomposition products thereof on organisms organs and cells
US7176303B2 (en) * 2003-11-06 2007-02-13 Isis Pharmaceuticals, Inc. Modulation of STAT5 expression
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
CA2413475C (en) 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
GB0216674D0 (en) * 2002-07-18 2002-08-28 Amersham Biosciences Uk Ltd Functional screening method
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
GB2423988A (en) 2003-07-18 2006-09-13 Cytokinetics Inc Characterizing biological stimuli by response curves
US20050014217A1 (en) 2003-07-18 2005-01-20 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
US7235353B2 (en) 2003-07-18 2007-06-26 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
US20050060100A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company Computer software and algorithms for systems biologically linked to cellular phenotype
US20050059083A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company High throughput method to identify ligands for cell attachment
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
US8586294B2 (en) 2004-05-18 2013-11-19 The Board Of Trustees Of The Leland Stanford Junior University Detection of protein translocation by beta-galactosidase reporter fragment complementation
US7323318B2 (en) 2004-07-15 2008-01-29 Cytokinetics, Inc. Assay for distinguishing live and dead cells
US8084260B2 (en) * 2004-11-24 2011-12-27 Applied Biosystems, Llc Spectral calibration method and system for multiple instruments
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
US20080227131A1 (en) * 2005-10-28 2008-09-18 Ge Healthcare Uk Limited Signalling Assay and Cell Line
US20090170091A1 (en) * 2006-01-17 2009-07-02 Kenneth Giuliano Method For Predicting Biological Systems Responses
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
CN101484806A (en) 2006-05-17 2009-07-15 协乐民公司 Method for automated tissue analysis
EP2095119A2 (en) * 2006-11-10 2009-09-02 Cellumen, Inc. Protein-protein interaction biosensors and methods of use thereof
US20100178652A1 (en) * 2007-01-05 2010-07-15 Litherland Sally A Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease
DK2120991T3 (en) * 2007-02-12 2014-04-28 Biotempt Bv TREATMENT OF TRAUMATIC BLEEDING WITH SHORT OLEGOPEPTIDES
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
JP5438962B2 (en) * 2008-12-25 2014-03-12 シスメックス株式会社 Cell image display device
WO2010078290A2 (en) * 2008-12-29 2010-07-08 President And Fellows Of Harvard College System for screening agonists/antagonists of cellular signaling pathways
KR101088605B1 (en) 2009-06-30 2011-11-30 한국산업기술대학교산학협력단 Cell manipulation method using two cameras
JP5089713B2 (en) * 2010-01-18 2012-12-05 シャープ株式会社 Image compression apparatus, compressed image output apparatus, image compression method, computer program, and recording medium
ES2739623T3 (en) 2011-03-17 2020-02-03 Cernostics Inc Systems and compositions for diagnosing Barrett's esophagus and methods for using them
WO2013138684A1 (en) 2012-03-15 2013-09-19 Montana Molecular Llc Genetically encoded fluorescent sensors for detecting intracellular signalling through diacylglycerol pathways
EP2682187B1 (en) * 2012-07-02 2017-09-13 Molecular Devices, LLC Selection method and apparatus
EP3738971B1 (en) 2013-11-04 2024-07-17 Montana Molecular LLC Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through camp pathways
DE102014012130B3 (en) 2014-08-13 2015-03-05 Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung Detection method using recombinant living cells for the detection of xenobiotic substances and arrangement and test kit for performing the detection method
WO2022146025A1 (en) * 2020-12-30 2022-07-07 한국과학기술원 Composition for inhibiting metastasis and enhancing anticancer drug sensitivity

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001305A1 (en) * 1989-07-22 1991-02-07 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
WO1994023039A1 (en) * 1993-04-07 1994-10-13 The Institute Of Cancer Research: Royal Cancer Hospital Methods for screening of substances for therapeutic activity and yeast for use therein
WO1995007463A1 (en) * 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1996003649A1 (en) * 1994-07-22 1996-02-08 The University Of North Carolina At Chapel Hill Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME
WO1996023898A1 (en) * 1995-01-31 1996-08-08 Novo Nordisk A/S A method of detecting biologically active substances
WO1997011094A1 (en) * 1995-09-22 1997-03-27 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
WO1997020931A1 (en) * 1995-12-08 1997-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method and compositions for monitoring dna binding molecules in living cells
WO1997030074A1 (en) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation and use of sh3 binding peptides
WO1998002571A1 (en) * 1996-07-16 1998-01-22 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
WO1998030715A1 (en) * 1997-01-07 1998-07-16 California Institute Of Technology Optical sensors of cell signaling

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT321257B (en) 1971-05-26 1975-03-25 Koreska Gmbh W Plant for the recovery of volatile solvents
JPS57198544A (en) 1981-05-28 1982-12-06 Sony Corp Manufacture of magnetic recording medium
DE3240063A1 (en) 1981-11-02 1983-05-26 Basf Ag, 6700 Ludwigshafen Apparatus for producing a magnetogram carrier
JPS5880136A (en) 1981-11-02 1983-05-14 Fuji Photo Film Co Ltd Manufacture of magnetic recording material
JPH0656656B2 (en) 1983-10-03 1994-07-27 富士写真フイルム株式会社 Method of manufacturing magnetic recording medium
JPS6292132A (en) 1985-10-18 1987-04-27 Fuji Photo Film Co Ltd Manufacture of magnetic recording medium
US4923766A (en) 1988-03-29 1990-05-08 Canon Kabushiki Kaisha Process for preparing magnetic recording
DE4009797A1 (en) 1990-03-27 1991-10-02 Pagendarm Gmbh METHOD AND ARRANGEMENT FOR CONDENSING VAPOROUS SUBSTANCES
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5989835A (en) * 1997-02-27 1999-11-23 Cellomics, Inc. System for cell-based screening
DE69839501D1 (en) * 1997-02-27 2008-06-26 Cellomics Inc System for screening biological cells
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
WO1998045704A2 (en) * 1997-04-07 1998-10-15 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
WO2000049183A1 (en) * 1999-02-17 2000-08-24 Clontech Laboratories, Inc. FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION OF cAMP IN LIVING CELLS USING GFP VARIANTS
US6573059B1 (en) * 1999-06-04 2003-06-03 Rmf Dictagene S.A. Use of the regulatory subunit of the camp dependent protein kinase (PKA) from dictyostelium for camp measurements

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001305A1 (en) * 1989-07-22 1991-02-07 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
WO1994023039A1 (en) * 1993-04-07 1994-10-13 The Institute Of Cancer Research: Royal Cancer Hospital Methods for screening of substances for therapeutic activity and yeast for use therein
WO1995007463A1 (en) * 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1996003649A1 (en) * 1994-07-22 1996-02-08 The University Of North Carolina At Chapel Hill Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME
WO1996023898A1 (en) * 1995-01-31 1996-08-08 Novo Nordisk A/S A method of detecting biologically active substances
WO1997011094A1 (en) * 1995-09-22 1997-03-27 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
WO1997020931A1 (en) * 1995-12-08 1997-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method and compositions for monitoring dna binding molecules in living cells
WO1997030074A1 (en) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation and use of sh3 binding peptides
WO1998002571A1 (en) * 1996-07-16 1998-01-22 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
WO1998030715A1 (en) * 1997-01-07 1998-07-16 California Institute Of Technology Optical sensors of cell signaling

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAREY K L ET AL: "EVIDENCE USING A GREEN FLUORESCENT PROTEIN-GLUCOCORTICOID RECEPTOR CHIMERA THAT THE RAN/TC4 GTPASE MEDIATES AN ESSENTIAL FUNCTION INDEPENDENT OF NUCLEAR PROTEIN IMPORT", THE JOURNAL OF CELL BIOLOGY, vol. 133, no. 5, June 1996 (1996-06-01), pages 985 - 996, XP000670316 *
Direct visualization of the translocation of the gamma subspecies of protein kinase c in living cells using fusion proteins with green fluorescent protein.Meeting held at 22-23.03.97 *
GERISCH, GUENTHER ET AL: "Chemoattractant-controlled accumulation of coronin at the leading edge of Dictyostelium cells monitored using a green fluorescent protein-coronin fusion protein", CURR. BIOL. (1995), 5(11), 1280-5 CODEN: CUBLE2;ISSN: 0960-9822, XP002089510 *
HAN HTUN ET AL: "VISUALIZATION OF GLUCOCORTICOID RECEPTOR TRANSLOCATION AND INTRANUCLEAR ORGANIZATION IN LIVING CELLS WITH A GREEN FLUORESCENT PROTEIN CHIMERA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 10, May 1996 (1996-05-01), pages 4845 - 4850, XP002029560 *
OGAWA H ET AL: "LOCALIZATION, TRAFFICKING, AND TEMPERATURE-DEPENDENCE OF THE AEQUOREA GREEN FLUORESCENT PROTEIN IN CULTURES VERTEBRATE CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 25, 5 December 1995 (1995-12-05), pages 11899 - 11903, XP002029556 *
SAKAI, N. ET AL.: "Direct visualization of the translocation of the gamma subspecies of protein kinase c in living cells using fusion proteins with green fluorescent protein.", THE JOURNAL OF CELL BIOLOGY, vol. 139, no. 6, 15 December 1997 (1997-12-15), pages 1465 - 1476, XP002078902 *
SCHMIDT, D.J. ET AL.: "Dynamic analysis of alpha-PKC-GFP chimera translocation events in smooth muscle with ultra-high speed 3D fluorescence microscopy", FASEB JOURNAL, vol. 11, no. 3, 28 February 1997 (1997-02-28), pages A505, XP002077257 *
SIDOROVA, JULIA M. ET AL: "Cell cycle-regulated phosphorylation of Swi6 controls its nuclear localization", MOL. BIOL. CELL (1995), 6(12), 1641-58 CODEN: MBCEEV;ISSN: 1059-1524, XP002089512 *
TODA, TAKASHI ET AL: "The fission yeast sts5+ gene is required for maintenance of growth polarity and functionally interacts with protein kinase C and an osmosensing MAP kinase pathway", J. CELL SCI. (1996), 109(9), 2331-2342 CODEN: JNCSAI;ISSN: 0021-9533, XP002090292 *
WEBB, CHRIS D. ET AL: "Use of green fluorescent protein for visualization of cell-specific gene expression and subcellular protein localization during sporulation in Bacillus subtilis", J. BACTERIOL. (1995), 177(20), 5906-11 CODEN: JOBAAY;ISSN: 0021-9193, XP002089513 *
WESTPHAL, MONIKA ET AL: "Microfilament dynamics during cell movement and chemotaxis monitored using a GFP - actin fusion protein", CURR. BIOL. (1997), 7(3), 176-183 CODEN: CUBLE2;ISSN: 0960-9822, XP002090291 *

Also Published As

Publication number Publication date
DE69804446D1 (en) 2002-05-02
US20090023598A1 (en) 2009-01-22
ES2173573T3 (en) 2002-10-16
EP1199564A2 (en) 2002-04-24
EP0986753A2 (en) 2000-03-22
ATE354089T1 (en) 2007-03-15
AU6820998A (en) 1998-10-30
US6518021B1 (en) 2003-02-11
CA2286293C (en) 2004-04-06
DE69837118T2 (en) 2007-12-27
US8058008B2 (en) 2011-11-15
DK1435519T3 (en) 2007-06-11
DE69804446T3 (en) 2006-08-24
DK0986753T4 (en) 2005-12-19
JP2001522454A (en) 2001-11-13
EP0986753B1 (en) 2002-03-27
EP1435519A1 (en) 2004-07-07
EP1199564B1 (en) 2004-06-23
PT986753E (en) 2002-09-30
EP1199564A3 (en) 2002-05-08
WO1998045704A2 (en) 1998-10-15
ES2173573T5 (en) 2006-03-01
ATE269975T1 (en) 2004-07-15
DK0986753T3 (en) 2002-07-22
DE69824763T2 (en) 2005-07-07
DE69837118D1 (en) 2007-03-29
ES2191575T1 (en) 2003-09-16
DE69824763D1 (en) 2004-07-29
ES2191575T3 (en) 2005-02-01
CA2286293A1 (en) 1998-10-15
DE1199564T1 (en) 2003-11-27
DE69804446T2 (en) 2002-11-07
EP1435519B1 (en) 2007-02-14
EP0986753B2 (en) 2005-08-10
US20030082564A1 (en) 2003-05-01
ATE215227T1 (en) 2002-04-15
PT1199564E (en) 2004-10-29

Similar Documents

Publication Publication Date Title
AU6820998A (en) A method for extracting quantitative information relating to an influence on a cellular response
Turkowyd et al. A general mechanism of photoconversion of green‐to‐red fluorescent proteins based on blue and infrared light reduces phototoxicity in live‐cell single‐molecule imaging
Chen et al. Characterization of spectral FRET imaging microscopy for monitoring nuclear protein interactions
Slater et al. Global record of “ghost” nannofossils reveals plankton resilience to high CO2 and warming
Arcese et al. The form and function of song in female song sparrows
Edmunds et al. The tissue composition of Montastraea franksi during a natural bleaching event in the Florida Keys
DE69700902D1 (en) METHOD FOR DETECTING LIGAND COUPLE BINDING WITH INCREASED SENSITIVITY
Modenutti et al. Mixotrophic ciliates in an Andean lake: dependence on light and prey of an Ophrydium naumanni population
DE50210457D1 (en) DEVICE FOR REFERENCING FLUORESCENT SIGNALS
Rick et al. Collagen fingerprinting and the chumash billfish fishery, Santa Barbara Channel, California, USA
Hinrichs et al. Seasonal variations in energy levels and metabolic processes of two dominant Acropora species (A. spicifera and A. digitifera) at Ningaloo Reef
Sanger et al. Fine partitioning of epiphyte habitat within Johansson zones in tropical Australian rain forest trees
Grémare et al. Relationship between sedimentary organic matter and benthic fauna within the Gulf of Lion: synthesis on the identification of new biochemical descriptors of sedimentary organic nutritional value
Studinski et al. Environmental factors affecting the distribution of aquatic invertebrates in temporary ponds in Mammoth Cave National Park, Kentucky, USA
Celano et al. Seafinding revisited: how hatchling marine turtles respond to natural lighting at a nesting beach
Vánská et al. Photosystem II supercomplexes lacking light‐harvesting antenna protein LHCB5 and their organization in the thylakoid membrane
Smit et al. Reverse intersystem crossing of single deuterated perylene molecules in a dibenzothiophene matrix
Gronauer et al. A photocrosslinking probe to capture the substrates of caseinolytic protease P
Geltsch et al. Egg spotting pattern in common cuckoos and their great reed warbler hosts: a century perspective
Tuson et al. Addressing the Requirements of High‐Sensitivity Single‐Molecule Imaging of Low‐Copy‐Number Proteins in Bacteria
Wallrabe et al. IQGAP1 interactome analysis by in vitro reconstitution and live cell 3‐color FRET microscopy
Thaler et al. Quantitative linear unmixing of CFP and YFP from spectral images acquired with two‐photon excitation
Heatwole et al. Structure of micrometazoan assemblages in the Larsemann Hills, Antarctica
Teranishi Identification of possible light emitters in the gills of a bioluminescent fungus Mycena chlorophos
Lin et al. Superior robustness of ExEm‐spFRET to IIem‐spFRET method in live‐cell FRET measurement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998913541

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2286293

Country of ref document: CA

Ref country code: CA

Ref document number: 2286293

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 542276

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09417197

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998913541

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1998913541

Country of ref document: EP